Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroGel in Non-Metastatic Castrate Resistant Prostate Cancer
NCT00515112Phase 2Terminated
- Sponsor
- University of Chicago
- Start
- Jul 2007
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in prostate cancer (PCa) comparing AndroGel with Placebo (2 arms). Primary endpoint: Progression-Free Survival up to 5 years. Started Jul 2007; status: terminated.
02
Drugs
AndroForte
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00515112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00515112.